Previous 10 | Next 10 |
2023-08-14 05:45:30 ET Summary Coya Therapeutics is developing Treg-enhancing therapeutics to target diseases driven by inflammation, including in the central nervous system, including ALS. Coya Therapeutics' ALS drug could be approved based on pivotal phase 2 results and could po...
2023-08-10 14:45:13 ET Summary Cassava Sciences' core AD treatment candidate simufilam slowed cognitive decline compared to placebo (albeit non-significantly) and stabilized cognition over 18 months in mild patients, which is unprecedented compared to historical data. However, I a...
2023-08-03 18:15:55 ET Summary Cassava Sciences, Inc. is advancing Alzheimer's treatment simufilam, but the small study size and lack of statistical significance raise concerns. Despite $168.4 million in cash, Cassava's Q2 2023 net loss of $26.4 million and ongoing expenses highli...
2023-08-03 11:07:45 ET Cassava Sciences press release ( NASDAQ: SAVA ): Q2 GAAP EPS of -$0.63 misses by $0.05 . $168.4 Million in Cash and Cash Equivalents at June 30, 2023. For further details see: Cassava Sciences GAAP EPS of -$0.63 misses by $0.05
Results of a randomized, controlled trial of oral simufilam in Alzheimer’s disease announced July 2023. Over 1,587 patients now enrolled in Phase 3 studies of simufilam in Alzheimer’s disease, an increase of over 340 patients in the last three months. Completion of...
2023-07-28 16:00:00 ET Summary Mounjaro may rake in $25B of annualized sales by 2026, exceeding ABBV's Humira. This naturally explains Mr. Market's optimism surrounding the LLY's stock thus far. The same has been witnessed with NVO, with accelerating annualized obesity related rev...
2023-07-25 16:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-07-16 02:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-07-13 07:31:33 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The tech and growth segments of the market have been having a tremendous 2023 with one glaring exception. Traders have been choosing to avoid biotech stocks amid macroeconomic uncertainty a...
2023-07-12 09:45:03 ET Summary Cassava Sciences' results for mild Alzheimer's disease are better than placebo at 12 months but little better beyond this. Thus, there is no compelling reason to invest in the stock. Simufilam may help maintain cognition in those with mild cognitive ...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Boa...